S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.73 (+1.76%)
AAPL   116.89 (+0.93%)
MSFT   212.38 (+0.97%)
FB   267.00 (+1.95%)
GOOGL   1,487.27 (+1.48%)
AMZN   3,220.00 (+2.26%)
TSLA   448.05 (+4.44%)
NVDA   544.58 (+0.62%)
BABA   289.82 (-1.42%)
CGC   14.22 (-0.70%)
MU   47.93 (+2.07%)
GE   6.24 (+0.16%)
AMD   84.89 (+3.54%)
T   28.48 (-0.11%)
F   6.74 (+1.20%)
ACB   4.69 (+0.86%)
GILD   63.38 (+0.30%)
NFLX   527.00 (+5.39%)
DIS   123.50 (-0.47%)
BA   167.86 (+1.57%)
BAC   24.09 (+0.00%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.73 (+1.76%)
AAPL   116.89 (+0.93%)
MSFT   212.38 (+0.97%)
FB   267.00 (+1.95%)
GOOGL   1,487.27 (+1.48%)
AMZN   3,220.00 (+2.26%)
TSLA   448.05 (+4.44%)
NVDA   544.58 (+0.62%)
BABA   289.82 (-1.42%)
CGC   14.22 (-0.70%)
MU   47.93 (+2.07%)
GE   6.24 (+0.16%)
AMD   84.89 (+3.54%)
T   28.48 (-0.11%)
F   6.74 (+1.20%)
ACB   4.69 (+0.86%)
GILD   63.38 (+0.30%)
NFLX   527.00 (+5.39%)
DIS   123.50 (-0.47%)
BA   167.86 (+1.57%)
BAC   24.09 (+0.00%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.73 (+1.76%)
AAPL   116.89 (+0.93%)
MSFT   212.38 (+0.97%)
FB   267.00 (+1.95%)
GOOGL   1,487.27 (+1.48%)
AMZN   3,220.00 (+2.26%)
TSLA   448.05 (+4.44%)
NVDA   544.58 (+0.62%)
BABA   289.82 (-1.42%)
CGC   14.22 (-0.70%)
MU   47.93 (+2.07%)
GE   6.24 (+0.16%)
AMD   84.89 (+3.54%)
T   28.48 (-0.11%)
F   6.74 (+1.20%)
ACB   4.69 (+0.86%)
GILD   63.38 (+0.30%)
NFLX   527.00 (+5.39%)
DIS   123.50 (-0.47%)
BA   167.86 (+1.57%)
BAC   24.09 (+0.00%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.73 (+1.76%)
AAPL   116.89 (+0.93%)
MSFT   212.38 (+0.97%)
FB   267.00 (+1.95%)
GOOGL   1,487.27 (+1.48%)
AMZN   3,220.00 (+2.26%)
TSLA   448.05 (+4.44%)
NVDA   544.58 (+0.62%)
BABA   289.82 (-1.42%)
CGC   14.22 (-0.70%)
MU   47.93 (+2.07%)
GE   6.24 (+0.16%)
AMD   84.89 (+3.54%)
T   28.48 (-0.11%)
F   6.74 (+1.20%)
ACB   4.69 (+0.86%)
GILD   63.38 (+0.30%)
NFLX   527.00 (+5.39%)
DIS   123.50 (-0.47%)
BA   167.86 (+1.57%)
BAC   24.09 (+0.00%)
Log in
NASDAQ:MITO

Stealth BioTherapeutics Stock Forecast, Price & News

$1.30
-0.05 (-3.70 %)
(As of 10/1/2020 03:59 PM ET)
Add
Compare
Today's Range
$1.30
Now: $1.30
$1.32
50-Day Range
$1.32
MA: $1.55
$1.89
52-Week Range
$0.90
Now: $1.30
$14.41
Volume911 shs
Average Volume310,065 shs
Market Capitalization$45.54 million
P/E Ratio65.03
Dividend YieldN/A
Beta2.47
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MITO
CUSIPN/A
CIKN/A
Phone617-600-6888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.09 million
Book Value$0.49 per share

Profitability

Net Income$-71,730,000.00

Miscellaneous

Employees73
Market Cap$45.54 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.30
-0.05 (-3.70 %)
(As of 10/1/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

How has Stealth BioTherapeutics' stock been impacted by COVID-19?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MITO shares have decreased by 18.2% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Stealth BioTherapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Stealth BioTherapeutics
.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Stealth BioTherapeutics
.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its earnings results on Thursday, August, 6th. The company reported ($0.02) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.02).
View Stealth BioTherapeutics' earnings history
.

What price target have analysts set for MITO?

6 Wall Street analysts have issued 1 year price targets for Stealth BioTherapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Stealth BioTherapeutics' stock price to reach $8.17 in the next year. This suggests a possible upside of 528.2% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics
.

Are investors shorting Stealth BioTherapeutics?

Stealth BioTherapeutics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 26,100 shares, a decrease of 51.2% from the August 31st total of 53,500 shares. Based on an average trading volume of 156,300 shares, the days-to-cover ratio is presently 0.2 days.
View Stealth BioTherapeutics' Short Interest
.

Who are some of Stealth BioTherapeutics' key competitors?

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), TherapeuticsMD (TXMD), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACB).

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:
  • Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 55)
  • Mr. Robert J. Weiskopf, Chief Financial Officer (Age 69)
  • Mr. Henry Hess, Chief Legal Counsel
  • Dr. Ben R. Bronstein, Chief Medical Officer (Age 70)
  • Dr. Brian D. Blakey, Chief Bus. Officer (Age 58)

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $1.30.

How big of a company is Stealth BioTherapeutics?

Stealth BioTherapeutics has a market capitalization of $45.54 million and generates $21.09 million in revenue each year. The company earns $-71,730,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Stealth BioTherapeutics employs 73 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.